12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-06), Rain Oncology's 12-1 Month Momentum % is -87.90%.
The industry rank for Rain Oncology's 12-1 Month Momentum % or its related term are showing as below:
RAIN's 12-1 Month Momentum % is not ranked
in the Biotechnology industry.
Industry Median: -21.06
vs RAIN: -87.90
Competitive Comparison of Rain Oncology's 12-1 Month Momentum %
For the Biotechnology subindustry, Rain Oncology's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rain Oncology's 12-1 Month Momentum % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rain Oncology's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Rain Oncology's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Rain Oncology 12-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Rain Oncology's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Rain Oncology (Rain Oncology) Business Description
Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RAIN has been successfully added to your